Our research is organized around the cancers that affect our patients — enabling targeted discovery, specialized clinical trials, and translational breakthroughs for each disease.
Our breast cancer program integrates molecular subtyping, targeted therapy trials, and survivorship research to improve outcomes across all stages of disease.
Our haematological malignancy research covers leukaemias, lymphomas, and myelomas, with a focus on precision medicine and novel CAR-T cell therapies.
Our lung cancer program focuses on targeted therapy for driver mutations common in South Asian never-smokers and advanced immunotherapy approaches.
Our paediatric oncology program addresses the unique biology of childhood cancers, focusing on improving cure rates while reducing long-term treatment toxicity.
India bears the highest global burden of head and neck cancers. Our program combines de-intensification strategies with novel immunotherapy approaches.
Our women's cancer program addresses ovarian, cervical, and endometrial cancers through innovative early-detection methods and PARP-inhibitor–based therapies.
Our colorectal cancer program investigates the rising incidence of young-onset disease in India and develops precision medicine strategies for advanced-stage patients.
Our gastric cancer research addresses the high incidence of stomach cancer in southern India through molecular classification and novel perioperative treatment regimens.
Our bone cancer program combines limb-salvage surgery innovation with targeted therapies for osteosarcoma, Ewing sarcoma, and chondrosarcoma.
.png&w=96&q=75){kind=small}